TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2024-03-21
楊志新Yang, James Chih-Hsin
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
63筆
51
Liang SK, Ko JC, Yang JC, Shih JY. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer. 2019 Jul;133:103-109. doi: 10.1016/j.lungcan.2019.05.019. Epub 2019 May 17. PMID: 31200815.
52
Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW, Kim DH, Kang HN, Pyo KH, Shin EJ, Shim HS, Soo RA, Yang JC, Lee SS, Chang H, Kim MH, Hong MH, Kim HR, Cho BC. Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. EMBO Mol Med. 2019 Dec;11(12):e10581. doi: 10.15252/emmm.201910581. Epub 2019 Oct 21. PMID: 31633304; PMCID: PMC6895608.
53
Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 Jan;14(1):124-129. doi: 10.1016/j.jtho.2018.08.004. Epub 2018 Aug 21. PMID: 30138764.
54
Park K, Wan-Teck Lim D, Okamoto I, Yang JC. First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. Ther Adv Med Oncol. 2019 Apr 15;11:1758835919836374. doi: 10.1177/1758835919836374. PMID: 31019567; PMCID: PMC6466470.
55
Yang JC. Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment? Lancet Oncol. 2019 May;20(5):602-603. doi: 10.1016/S1470-2045(19)30085-3. Epub 2019 Apr 8. PMID: 30975629.
56
Lee JH, Chen HY, Hsu FM, Chen JS, Liao WY, Shih JY, Yu CJ, Chen KY, Tsai TH, Yang JC. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. Oncologist. 2019 Dec;24(12):e1417-e1425. doi: 10.1634/theoncologist.2019-0152. Epub 2019 May 24. PMID: 31127020; PMCID: PMC6975931.
57
Wu TH, Lee LJ, Yuan CT, Chen TW, Yang JC. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study. J Formos Med Assoc. 2019 Jan;118(1 Pt 2):230-236. doi: 10.1016/j.jfma.2018.04.001. Epub 2018 Apr 27. PMID: 29709339.
58
Yang JC, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, Collins B, Pisetzky F, Horn L. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019 May;14(5):933-939. doi: 10.1016/j.jtho.2019.02.001. Epub 2019 Feb 11. PMID: 30763730.
59
Ma WL, Lin CC, Hsu FM, Lee JM, Chen JS, Hsieh MS, Chang YL, Chao YT, Chang CH, Chih-Hsin Yang J. Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study. Clin Lung Cancer. 2019 Nov;20(6):e609-e618. doi: 10.1016/j.cllc.2019.06.011. Epub 2019 Jul 10. PMID: 31377141.
60
Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol. 2019 Jun;145(6):1569-1579. doi: 10.1007/s00432-019-02862-x. Epub 2019 Feb 19. PMID: 30783814; PMCID: PMC6527523.
